Figure 6 | Scientific Reports

Figure 6

From: Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay

Figure 6

Mutations in the rHC/A SV2 binding site affects FGFR3c dimerization. A BoNT/A binding domain SV2 mutant variant (rHC/A T1145A;T1146A) (black) has reduced ability to dimerize FGFR3c compared to a wild-type BoNT/A binding domain (rHC/A) (green), EC50 = 78 nM (95% CI; 53, 115) vs 27 nM (95% CI; 18, 41). Points represent the average normalized brightness values ± SD from greater than 30 cells collected on 4 independent days.

Back to article page